Same active ingredient (semaglutide); different products with different FDA-approved indications. Ozempic: type 2 diabetes (and CV risk reduction in T2D+CVD). Wegovy: chronic weight management plus, since March 2024, cardiovascular event reduction in adults with obesity (BMI ≥27) and established CVD.
Side-by-side
| Dimension | Ozempic | Wegovy |
|---|---|---|
| Editorial score | 0/100 | 0/100 |
| Semaglutide | T2D · ~$968/mo list | Weight + CV · ~$1,349/mo list |
| Tirzepatide | — | — |
Who should pick Ozempic
Patients with type 2 diabetes — Ozempic is the right product. Most commercial insurance covers Ozempic for T2D.
Who should pick Wegovy
Patients with obesity (without diabetes), or obesity + established CVD — Wegovy under the March 2024 indication. Medicare Part D coverage expanded April 2026.
Frequently asked
Same drug?
Same active ingredient (semaglutide). Different products with different FDA-approved doses and indications.
Can you use Ozempic off-label for weight?
It happens but isn't FDA-approved labeling. Wegovy is the approved product.
Does insurance cover Wegovy?
Variable. Many commercial plans cover with PA. Medicare Part D coverage expanded April 2026 for adults with BMI ≥27 + established CVD.